The reduction in tumor burden and increased survival that we observed using the CHRNA7 agonist AR-R17779 in combination with an immune checkpoint inhibitor suggested that tumor-associated CHRNA7+ immune cells are novel therapeutic targets.23 The gene discussed is CHRNA7; the disease is neoplasm.